BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34544437)

  • 1. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
    Luo F; Zeng KM; Cao JX; Zhou T; Lin SX; Ma WJ; Yang YP; Zhang ZH; Lu FT; Huang Y; Zhao HY; Zhang L
    Lipids Health Dis; 2021 Sep; 20(1):109. PubMed ID: 34544437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer.
    Li X; Tang H; Wang J; Xie X; Liu P; Kong Y; Ye F; Shuang Z; Xie Z; Xie X
    Breast; 2017 Apr; 32():1-6. PubMed ID: 27939967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases.
    Wang Y; Wang ZQ; Wang FH; Lei XF; Yan SM; Wang DS; Zhang F; Xu RH; Wang LY; Li YH
    Oncotarget; 2016 Aug; 7(35):57290-57300. PubMed ID: 27344180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of preoperative serum high density lipoprotein cholesterol levels in soft tissue sarcoma.
    Que Y; Jiang F; Liu L; Li Y; Chen Y; Qiu H; Zhou Z; Zhang X
    Medicine (Baltimore); 2015 May; 94(18):e844. PubMed ID: 25950696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma.
    Chi PD; Liu W; Chen H; Zhang JP; Lin Y; Zheng X; Liu W; Dai S
    PLoS One; 2014; 9(3):e91080. PubMed ID: 24625581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
    Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
    Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients.
    Mao M; Wang X; Sheng H; Liu Y; Zhang L; Dai S; Chi PD
    BMC Cancer; 2018 Nov; 18(1):1178. PubMed ID: 30486825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.
    Sniderman AD; Islam S; McQueen M; Pencina M; Furberg CD; Thanassoulis G; Yusuf S
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27737874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of preoperative serum triglyceride, high-density lipoprotein, and low-density lipoprotein levels in lung squamous cell carcinoma.
    Li Z; Xu J; Feng W; Ma Z; Wu Y; Zhu T; Xu P; Dong L; Ding J; Zhou J; Yu G
    Sci Rep; 2022 Oct; 12(1):16828. PubMed ID: 36207435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
    Soran H; France MW; Kwok S; Dissanayake S; Charlton-Menys V; Younis NN; Durrington PN
    Ann Clin Biochem; 2011 Nov; 48(Pt 6):566-71. PubMed ID: 22006975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study.
    Ma C; Wang X; Guo J; Liu P
    Lipids Health Dis; 2021 Oct; 20(1):69. PubMed ID: 34598703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer.
    Lin Q; Liu W; Xu S; Sun L
    Arch Gynecol Obstet; 2022 Mar; 305(3):683-691. PubMed ID: 34453586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study.
    Wu TT; Zheng YY; Yang YN; Li XM; Ma YT; Xie X
    Metab Syndr Relat Disord; 2019 May; 17(4):223-231. PubMed ID: 30720383
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
    Yan S; Shun-Chang J; Li C; Jie L; Ya-Li L; Ling-Xiong W
    BMC Cancer; 2010 Nov; 10():621. PubMed ID: 21067592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients.
    Lv Y; Ding XS; Li Y; An X; Miao LY
    Cancer Biomark; 2016; 16(1):89-97. PubMed ID: 26835709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 18. Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism.
    Zabłocka-Słowińska K; Płaczkowska S; Skórska K; Prescha A; Pawełczyk K; Porębska I; Kosacka M; Grajeta H
    PLoS One; 2019; 14(4):e0215246. PubMed ID: 30973911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative Serum Triglyceride to High-Density Lipoprotein Cholesterol Ratio Can Predict Prognosis in Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
    Li J; Ma C; Yuan X; Wang X; Li N; Yu R; Liao H
    Curr Oncol; 2022 Aug; 29(9):6125-6136. PubMed ID: 36135050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.